Meet the guy biohacking puppies to make them glow in the dark
By Kristen V. Brown,
Fusion
| 09. 28. 2016
It was after a home invasion almost a decade ago that David Ishee first got interested in breeding dogs. A burglar with a gun had broken into his home in Jackson, Mississippi, where Ishee was asleep along with his wife, 3-year-old-daughter and newborn son. Ishee pulled out his own shotgun and scared the would-be thief off. But he was unsettled wondering what might have happened had he not been around.
Ishee wanted a guard dog, and giant, docile mastiffs are good ones to have around little kids. Like so many carefully bred dogs, though, mastiffs are riddled with genetic disorders. So Ishee decided to start breeding them himself, with plans to increase their genetic diversity and hopefully make them healthier, happier and more fit. Over just a few generations, he saw results. Gone was the sagging skin and oversized head that makes so many mastiffs look goofy. He told me his dogs could jump higher and run faster than most other Mastiffs can.
But because the majority of the genetic disorders dogs suffer from are recessive, Ishee...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...